Хайлтын үр дүнгүүд - Michael Schlichting
- 8-н 1 - 8 үр дүнгүүдийг харуулж байна
-
1
-
2
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials -н Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, Fortunato Ciardiello, S. Heeger, Michael Schlichting, İlhan Çelik, Claus‐Henning Köhne
Хэвлэсэн 2012Artigo -
3
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i... -н Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, I. Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, İlhan Çelik, Philippe Rougier, Fortunato Ciardiello
Хэвлэсэн 2011Artigo -
4
Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study -н Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, F. Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello
Хэвлэсэн 2012Artigo -
5
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the J... -н Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, Natalia Jacob, Jason Hoffman, Karin Tyroller, Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles
Хэвлэсэн 2025Artigo -
6
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer -н Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier
Хэвлэсэн 2009Artigo -
7
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study -н Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley
Хэвлэсэн 2017Artigo -
8
Single-cell chromatin accessibility identifies pancreatic islet cell type– and state-specific regulatory programs of diabetes risk -н Joshua Chiou, Chun Zeng, Cheng Zhang, Jee Yun Han, Michael Schlichting, Michael Miller, Robert Mendez, Serina Huang, Jinzhao Wang, Yinghui Sui, Allison Deogaygay, Mei-Lin Okino, Yunjiang Qiu, Ying Sun, Parul Kudtarkar, Rongxin Fang, Sebastian Preißl, Maike Sander, David U. Gorkin, Kyle J. Gaulton
Хэвлэсэн 2021Artigo
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Cancer
Internal medicine
Medicine
Oncology
Cetuximab
Colorectal cancer
Confidence interval
Hazard ratio
KRAS
Avelumab
Bladder cancer
Chemotherapy
FOLFIRI
Fluorouracil
Immunotherapy
Irinotecan
Metastatic Urothelial Carcinoma
Pembrolizumab
Urothelial carcinoma
Adverse effect
Astrobiology
Beta cell
Biology
Cell
Cell type
Chromatin
Computational biology
DNA methylation
Dermatology
Endocrinology